Nine months post-launch and two weeks after announcing its plans for an IPO, the New York Citybased weight-loss company said Monday that it is seeking a $1.78 billion valuation and a $250 million raise
0.5mg x 12 weeks $690.00 G
doi:10.3748/wjg.v31.i37.111435
Combining therapies has yielded compelling results, and compounded medications can be personalized to meet the needs of each patient, offering a unique solution for various medication related concerns
See how it may aid weight loss, brain health, and boost athletic performance
Ethics declarations Funding VSS is supported by a Department of Medicine Eliot Phillipson Clinician-Scientist Training Program, a Banting and Best Diabetes Centre Postdoctoral Fellowship at the University of Toronto and a Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award